^
    Back
    Association details:
    Biomarker:RB1 mutation
    Cancer:Triple Negative Breast Cancer
    Drug:carboplatin (Tubulin polymerization promoter) +
    docetaxel (Tubulin polymerization promoter, Microtubule stabilizer)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Breast Cancer Res Treat
    Title:

    Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer

    Published date:
    06/26/2021
    Excerpt:
    Patients with clinical stages II/III TNBC received 6 cycles of docetaxel and carboplatin....EGFR, RB1, RAD51AP2, SDK2, L1CAM, KPRP, PCDHA1, CACNA1S, CFAP58, COL22A1, and COL4A5 mutations were observed almost exclusively in pre-treatment samples from patients who achieved pCR.
    DOI:
    10.1007/s10549-021-06307-3
    Trial ID:
    NCT02124902